CD19 CAR-T Therapy for Refractory Pemphigus Vulgaris

Jinbo Chen3 enrolled

Overview

This is an investigator-initiated, single-center, single-arm, open-label exploratory clinical study designed to evaluate the safety, tolerability, and preliminary efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.

This is an investigator-initiated, open-label, single-center, single-arm exploratory interventional study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immune reconstitution, and preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in adult patients with moderate-to-severe refractory pemphigus vulgaris. Eligible participants are adults with refractory pemphigus vulgaris. After enrollment, participants will undergo leukapheresis for ex vivo manufacturing of autologous CD19 CAR-T cells. After product release, participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide within 2 to 7 days prior to CAR-T infusion. Participants will receive a single intravenous infusion of autologous CD19 CAR-T cells at a protocol-defined dose (1 X 10\^6 CAR-positive T cells per kilogram of body weight). Premedication may be administered at investigator discretion. No comparator group is included. Participants will be followed for up to 96 weeks after infusion. Safety assessments include monitoring for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, and other treatment-emergent adverse events. Efficacy assessments include changes in PDAI score, disease control, Physician Global Assessment (PGA), Autoimmune Bullous Skin Disorder Intensity Score (ABSIS), relapse rate, time to relapse, and corticosteroid-sparing effects. Translational assessments include peripheral CD19-positive B-cell depletion and reconstitution, B-cell subset dynamics, serum anti-desmoglein 1 and 3 antibody levels, and serum cytokine profiles. CAR-T pharmacokinetics will be evaluated through CAR transgene copy number and circulating CAR-positive T-cell detection, including expansion and persistence metrics.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Pemphigus Vulgaris

Interventions

Autologous CD19 CAR-T cellsBIOLOGICAL

Autologous CD19 CAR-T cells are manufactured ex vivo using the participant's own T cells collected by leukapheresis. The CAR construct targets CD19-expressing B cells and consists of a single-chain variable fragment directed against CD19. Participants will receive lymphodepleting chemotherapy with fludarabine and cyclophosphamide prior to CAR-T cell infusion according to the protocol-defined schedule. Following completion of lymphodepletion, each participant will receive a single intravenous infusion of autologous CD19 CAR-T cells under inpatient monitoring. Premedication, including acetaminophen and diphenhydramine, may be administered prior to infusion at the investigator's discretion in accordance with institutional practice.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 70 Years

Medical Language ↔ Plain English

Inclusion Criteria: Participants must meet all of the following criteria: 1. Ability to provide written informed consent. 2. Age 18 to 70 years at screening, male or female. 3. Diagnosis of pemphigus vulgaris confirmed by clinical presentation, histopathology, direct immunofluorescence (DIF), and positive anti-desmoglein 3 and/or anti-desmoglein 1 antibodies. 4. Moderate-to-severe disease activity defined as Pemphigus Disease Area Index (PDAI) ≥ 15 at screening. 5. Refractory pemphigus vulgaris is defined as inadequate response, disease relapse, or treatment dependence following systemic corticosteroids and rituximab-based therapy for at least 6 months, with persistent disease activity meeting at least one of the following criteria: 1. Ongoing active disease with the appearance of new erythema, blisters, or erosions; 2. Persistently elevated anti-desmoglein 1 or anti-desmoglein 3 antibody titers \> 100 U/mL; 3. Inability to taper systemic corticosteroids to \< 20 mg/day prednisone equivalent (i.e., ≥ 4 tablets/day of standard prednisone dosing). 6. Requirement for systemic therapy at screening due to active disease. 7. Adequate vascular access for leukapheresis. 8. Life expectancy greater than 6 months. 9. Participants must have adequate organ function as defined below: 1. Hematologic function: absolute neutrophil count ≥ 1.0 × 10⁹/L, platelet count ≥ 50 × 10⁹/L, hemoglobin ≥ 80 g/L. 2. Renal function: Creatinine clearance ≥ 40 mL/min. 3. Hepatic function: ALT and AST ≤ 2.5 × upper limit of normal; total bilirubin ≤ 1.5 × upper limit of normal. 4. Cardiac function: Left ventricular ejection fraction (LVEF) ≥ 50% with no clinically significant cardiac dysfunction. 5. Pulmonary function: Dyspnea ≤ Grade 1 (CTCAE v5.0) and oxygen saturation (SpO₂) ≥ 92% on room air. 6. Coagulation function: international normalized ratio (INR) and activated partial thromboplastin time (aPTT) ≤ 1.5 × upper limit of normal, with no clinically significant coagulopathy. 9\. No evidence of clinically significant active infection at baseline evaluation. 10\. Reproductive Criteria: Women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) test within 48 hours prior to initiation of lymphodepleting chemotherapy. Women of childbearing potential must agree to use effective contraception during study participation and for at least 12 months after CAR-T infusion. Male participants must agree to use effective contraception and avoid sperm donation during study participation and for at least 12 months after infusion. Exclusion Criteria: Participants meeting any of the following criteria will be excluded: 1. Active uncontrolled infection at screening, requiring systemic antimicrobial therapy. Participants with active tuberculosis, hepatitis C virus (HCV), human immunodeficiency virus (HIV), or syphilis infection will be excluded. Participants with hepatitis B surface antigen and/or hepatitis B core antibody positivity may be eligible only if HBV DNA is below the lower limit of quantification and appropriate antiviral prophylaxis is provided at the investigator's discretion. 2. History of other active autoimmune disease requiring systemic immunosuppression. 3. Previous treatment with any gene-modified cellular therapy, including CAR-T or CAR-NK therapy. 4. Prior allogeneic stem cell or solid organ transplantation. 5. Severe or uncontrolled cardiovascular, pulmonary, hepatic, or renal disease that would increase risk associated with lymphodepleting chemotherapy or CAR-T cell infusion. 6. Use of high-dose systemic corticosteroids (\>1 mg/kg/day prednisone equivalent) within 7 days prior to leukapheresis. 7. Use of rituximab or other B-cell-targeted biologics within protocol-defined washout period. 8. Use of intravenous immunoglobulin, plasma exchange, or other intensive immunomodulatory therapy within 2 weeks prior to leukapheresis. 9. Received live vaccine within 8 weeks prior to screening. 10. History of malignancy within 5 years prior to enrollment, except adequately treated non-melanoma skin cancer or in situ carcinoma. 11. Pregnancy or breastfeeding. 12. Known hypersensitivity to any component of lymphodepleting chemotherapy or CAR-T cell product. 13. Any condition that, in the investigator's judgment, would compromise patient safety or study integrity.

Locations (1)

Traditional Chinese and Western Medicine Hospital of Wuhan, Wuhan, Hubei

Wuhan, Hubei, China

RECRUITING

Outcomes

Primary Outcomes

Incidence and Severity of Treatment-Emergent Adverse Events

Treatment-emergent adverse events, serious adverse events, dose-limiting toxicities, cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, infections, cytopenias, organ toxicities, infusion-related reactions, and clinically significant laboratory abnormalities will be assessed. Adverse events will be graded according to CTCAE v5.0, and immune effector cell-related toxicities will be assessed according to applicable consensus grading criteria.

Time frame: From initiation of lymphodepleting chemotherapy through Day 90 after CAR-T cell infusion

Change From Baseline in PDAI Score at Week 12

The change from baseline in Pemphigus Disease Area Index (PDAI) score at Week 12 will be assessed to evaluate preliminary clinical efficacy of autologous CD19 CAR-T cell therapy in patients with refractory pemphigus vulgaris.

Time frame: Baseline and Week 12

Proportion of participants achieving disease control at Week 4 after CAR-T infusion

Disease control is defined as cessation of new active cutaneous or mucosal lesions with established lesion healing or no further progression of existing lesions, as assessed by the investigator. This endpoint evaluates the early clinical response following CD19 CAR-T cell therapy and reflects initial disease stabilization after B-cell depletion.

Time frame: Week 4

Secondary Outcomes

Change From Baseline in Pemphigus Disease Area Index （PDAI） Score Over Time (Range 0-263)

Changes from baseline in Pemphigus Disease Area Index (PDAI) score will be assessed at scheduled follow-up visits to evaluate the durability of clinical response. The total PDAI score ranges from 0 to 263, with higher scores indicating more severe disease.

Time frame: Baseline through Week 96 after CAR-T cell infusion

Change From Baseline in Physician Global Assessment Score (PGA) (Range 0-10)

Central Contacts

Jinbo Chen, MD, PhD

CONTACT

+86 188 2736 3048 chen999jb@163.com

Xiaoya Du

CONTACT

+86 27 8533 2028

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.